Avian influenza A(H7N9)virus:from low pathogenic to highly pathogenic  

作　　者：William J.Liu Haixia Xiao Lianpan Dai Di Liu Jianjun Chen Xiaopeng Qi Yuhai Bi Yi Shi George F.Gao Yingxia Liu 

机构地区：[1]Shenzhen Key Laboratory of Pathogen and Immunity,Shenzhen Third People’s Hospital,Shenzhen,518114,China [2]National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China [3]Laboratory of Protein Engineering and Vaccines,Tianjin Institute of Industrial Biotechnology,Chinese Academy of Sciences(CAS),Tianjin,300308,China [4]CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing,100101,China [5]CAS Key Laboratory of Special Pathogens and Biosafety,Chinese Academy of Sciences,Wuhan,430071,China [6]National Virus Resource Center,Chinese Academy of Sciences,Wuhan,430071,China [7]University of Chinese Academy Sciences,Beijing,100049,China [8]Center for Influenza Research and Early Warning,Chinese Academy of Sciences,Beijing,100101,China [9]Chinese Center for Disease Control and Prevention,Beijing,102206,China

出　　处：《Frontiers of Medicine》2021年第4期507-527,共21页医学前沿（英文版）

基　　金：This study was supported by the Shenzhen Science and Technology Research and Development Project(No.JCYJ201604271519-20801);Innovation Unit for Emerging and Re-emerging Virus Adaptive Evolution Study and the Applications in Disease Control(No.2019-I2M-5-009);National Mega-projects for Infectious Diseases(No.2020ZX10001016-005-001);W.J.L.is supported by the Excellent Young Scientist Program of the NSFC(No.81822040)and Beijing New-star Plan of Science and Technology(No.Z181100006218080);H.X.is supported by Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project(No.TSBICIP-KJGG-004-04);G.F.G.is a leading principal investigator of the National Natural Science Foundation of China Innovative Research Group(No.81621091).

摘　　要：OriginalTranslation The avian influenza A(H7N9)virus is a zoonotic virus that is closely associated with live poultry markets.It has caused infections in humans in China since 2013.Five waves of the H7N9 influenza epidemic occurred in China between March 2013 and September 2017.H7N9 with low-pathogenicity dominated in the first four waves,whereas highly pathogenic H7N9 influenza emerged in poultry and spread to humans during the fifth wave,causing wide concern.Specialists and officials from China and other countries responded quickly,controlled the epidemic well thus far,and characterized the virus by using new technologies and surveillance tools that were made possible by their preparedness efforts.Here,we review the characteristics of the H7N9 viruses that were identified while controlling the spread of the disease.It was summarized and discussed from the perspectives of molecular epidemiology,clinical features,virulence and pathogenesis,receptor binding,T-cell responses,monoclonal antibody development,vaccine development,and disease burden.These data provide tools for minimizing the future threat of H7N9 and other emerging and re-emerging viruses,such as SARS-CoV-2.

关 键 词：H7N9 HPAIV clinical features epidemiology HEMAGGLUTININ immunity PATHOGENESIS VACCINE 

分 类 号：R511.7[医药卫生—内科学]